Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash & Current Investments: 2019-2025

Historic Cash & Current Investments for Legend Biotech (LEGN) over the last 7 years, with Sep 2025 value amounting to $278.9 million.

  • Legend Biotech's Cash & Current Investments rose 128.80% to $278.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 852.54%. This contributed to the annual value of $286.7 million for FY2024, which is 77.57% down from last year.
  • According to the latest figures from Q3 2025, Legend Biotech's Cash & Current Investments is $278.9 million, which was up 4.62% from $266.6 million recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Cash & Current Investments registered a high of $1.3 billion during Q4 2023, and its lowest value of -$1.2 billion during Q2 2024.
  • For the 3-year period, Legend Biotech's Cash & Current Investments averaged around $360.1 million, with its median value being $441.7 million (2025).
  • In the last 5 years, Legend Biotech's Cash & Current Investments slumped by 382.89% in 2022 and then skyrocketed by 412.57% in 2023.
  • Over the past 5 years, Legend Biotech's Cash & Current Investments (Quarterly) stood at $688.9 million in 2021, then surged by 41.03% to $971.6 million in 2022, then skyrocketed by 31.57% to $1.3 billion in 2023, then tumbled by 77.57% to $286.7 million in 2024, then skyrocketed by 128.80% to $278.9 million in 2025.
  • Its last three reported values are $278.9 million in Q3 2025, $266.6 million for Q2 2025, and $441.7 million during Q1 2025.